Hanyang Med Rev.  2011 Aug;31(3):177-189. 10.7599/hmr.2011.31.3.177.

Infection Control for Healthcare-Associated Infections in Pediatric Patients

• Oh SH

• KMID: 2168195
• DOI: http://doi.org/10.7599/hmr.2011.31.3.177

Abstract

The history of healthcare-associated infections in children is tied closely to the progress of medicine itself. With the advent of crucial invasive procedures and new therapies, longer survival from conditions formerly causing early death are noticed and at the same time have also increased the numbers of immunocompromised children with impaired host defenses resulting in healthcare-associated infections as the leading causes of mortality and morbidity in pediatric and neonatal intensive care units. Widespread use of new broad-spectrum antimicrobial agents has caused the rise of antibiotic resistant microorganisms and fungi as the etiologies of healthcare-associated infections. A number of pediatric collaborative studies have thus been done to attain optimal practices that result in decreasing rates of healthcare-associated infections. Furthermore, emerging evidence about risk factors for various healthcare-associated infections in children is guiding us in targeting adjunctive preventive intervention. Prevention of healthcare-associated infections is based on infection control strategies that aim to limit susceptibility to infections by enhancing host defenses, interrupting transmission of organisms by healthcare workers and by promoting the judicious use of antimicrobials. With changes in the risk factors for healthcare-associated infections, more studies on Korean children are needed to provide the optimal tools for better outcome.

Keyword

Infection Control; Child; Infant; Risk Factors

MeSH Terms

Anti-Infective Agents
Child
Delivery of Health Care
Fungi
Humans
Infant
Infant, Newborn
Infection Control
Intensive Care Units, Neonatal
Risk Factors
Anti-Infective Agents

Reference

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004. 32:470–485.

2. Park SE, Jeon GW, Choi CW, Hwang JH, Koo SH, Kim YJ, et al. Evaluation of perinatal and management factors associated with improved survival in extremely low birth weight infants. Korean J Pediatr. 2005. 48:1324–1329.

3. Lee HY, Lee GY, Kim MJ, Jeon GW, Shim JW, Chang YS, et al. The Effect of Early Enteral Trophic Feeding within 24 Hours after Birth in Extremely Low Birth Weight Infants of 26 Weeks and Less, and Birth Weight below 1,000 g. J Korean Soc Neonatol. 2007. 14:59–65.

4. Seo JH, Nam GY, Park KH, Byun SY, Park SE. Colonization rate and control of vancomycin-resistant enterococci in the neonatal intensive care unit. Korean J Pediatr Infect Dis. 2010. 17:1–8.

5. Gaynes RP, Edwards JR, Jarvis WR, Culver DH, Tolson JS, Martone WJ. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics. 1996. 98:357–361.

6. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics. 1999. 103:e39.

7. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1999. 27:279–284.

8. Siegel JD, Krishner KK, Levine GL. Prevalence of antimicrobial resistant bacteria in pediatric prevention network intensive care units. 2001. In : The 39th Annual Meeting of the Infectious Diseases Society of America; 2001 Oct 25-28; IDSA. San Francisco: IDSA;–92.

9. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006. 42:389–391.

10. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006. 355:666–674.

11. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997. 40:135–136.

12. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008. 46:668–674.

13. Garrett DO, Jochimsen E, Murfitt K, Hill B, McAllister S, Nelson P, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol. 1999. 20:167–170.

14. Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992. 36:1991–1996.

15. Shannon K, Fung K, Stapleton P, Anthony R, Power E, French G. A hospital outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae investigated by RAPD typing and analysis of the genetics and mechanisms of resistance. J Hosp Infect. 1998. 39:291–300.

16. Pai H, Kim MR, Seo MR, Choi TY, Oh SH. A nosocomial outbreak of Escherichia coli producing CTX-M-15 and OXA-30 beta-lactamase. Infect Control Hosp Epidemiol. 2006. 27:312–314.

17. Hall CB, Douglas RG Jr, Geiman JM, Messner MK. Nosocomial respiratory syncytial virus infections. N Engl J Med. 1975. 293:1343–1346.

18. Langley JM, LeBlanc JC, Wang EE, Law BJ, MacDonald NE, Mitchell I, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study. Pediatrics. 1997. 100:943–946.

19. Wilson CW, Stevenson DK, Arvin AM. A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. Pediatr Infect Dis J. 1989. 8:24–29.

20. Cox RA, Rao P, Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect. 2001. 48:186–192.

21. Deville JG, Cherry JD, Christenson PD, Pineda E, Leach CT, Kuhls TL, et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis. 1995. 21:639–642.

22. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004. 32:470–485.

23. Janes M, Kalyn A, Pinelli J, Paes B. A randomized trial comparing peripherally inserted central venous catheters and peripheral intravenous catheters in infants with very low birth weight. J Pediatr Surg. 2000. 35:1040–1044.

24. Garland JS, Alex CP, Sevallius JM, Murphy DM, Good MJ, Volberding AM, et al. Cohort study of the pathogenesis and molecular epidemiology of catheter-related bloodstream infection in neonates with peripherally inserted central venous catheters. Infect Control Hosp Epidemiol. 2008. 29:243–249.

25. Randolph AG, Brun-Buisson C, Goldmann D. Identification of central venous catheter-related infections in infants and children. Pediatr Crit Care Med. 2005. 6:S19–S24.

26. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006. 355:2725–2732.

27. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011. 39:S1–S34.

28. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Healthcare Infection Control Practices Advisory Committee. Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: recommendations of CDC and The Healthcare Infection Control Practices Advisor y Committee. Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee[Internet]. c2011. cited 2011 Apr 25. Atlanta(US): Centers for Disease Control and Prevention;Available from:http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/CDCpneumo_guidelines.pdf.

29. Straube RC, Thompson MA, Van Dyke RB, Wadell G, Connor JD, Wingard D, et al. Adenovirus type 7b in a children's hospital. J Infect Dis. 1983. 147:814–819.

30. Curley MA, Schwalenstocker E, Deshpande JK, Ganser CC, Bertoch D, Brandon J, et al. Tailoring the Institute for Health Care Improvement 100,000 Lives Campaign to pediatric settings: the example of ventilator-associated pneumonia. Pediatr Clin North Am. 2006. 53:1231–1251.

31. Davies HD, Jones EL, Sheng RY, Leslie B, Matlow AG, Gold R. Nosocomial urinary tract infections at a pediatric hospital. Pediatr Infect Dis J. 1992. 11:349–354.

32. Lohr JA, Donowitz LG, Sadler JE 3rd. Hospital-acquired urinary tract infection. Pediatrics. 1989. 83:193–199.

33. Wong ES. Guideline for prevention of catheter-associated urinary tract infections. Am J Infect Control. 1983. 11:28–36.

34. Bhattacharyya N, Kosloske AM, Macarthur C. Nosocomial infection in pediatric surgical patients: a study of 608 infants and children. J Pediatr Surg. 1993. 28:338–343. discussion 43-4.

35. Pollock EM, Ford-Jones EL, Rebeyka I, Mindorff CM, Bohn DJ, Edmonds JF, et al. Early nosocomial infections in pediatric cardiovascular surgery patients. Crit Care Med. 1990. 18:378–384.

36. Odio C, McCracken GH Jr, Nelson JD. CSF shunt infections in pediatrics. A seven-year experience. Am J Dis Child. 1984. 138:1103–1108.

37. Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev. 2007. CD004985.

38. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002. 346:1871–1877.

39. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992. 326:281–286.

40. Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008. 121:915–923.

41. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. Pediatrics. 2001. 107:14–22.

42. Goldmann DA. Prevention and management of neonatal infections. Infect Dis Clin North Am. 1989. 3:779–813.

43. Millar MR, Bacon C, Smith SL, Walker V, Hall MA. Enteral feeding of premature infants with Lactobacillus GG. Arch Dis Child. 1993. 69:483–487.

44. Reuman PD, Duck wor, Smith KL, Kagan R, Bucciarelli RL, Ayoub EM. Lack of effect of Lactobacillus on gastrointestinal bacterial colonization in premature infants. Pediatr Infect Dis. 1986. 5:663–668.

45. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004. CD000361.

46. Carr R, Modi N, Dore CJ, El-Rifai R, Lindo D. A randomized, controlled trial of prophylactic granulocyte-macro phage colony-stimulating factor in human newborns less than 32 weeks gestation. Pediatrics. 1999. 103:796–802.

47. Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics. 2001. 107:30–35.